Natera (NASDAQ:NTRA) Announces Earnings Results, Beats Expectations By $0.02 EPS

Natera (NASDAQ:NTRA) announced its earnings results on Friday. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02, FiscalAI reports. Natera had a negative net margin of 7.11% and a negative return on equity of 11.82%. The business had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. During the same period last year, the firm posted ($0.74) earnings per share. Natera’s quarterly revenue was up 37.7% on a year-over-year basis.

Natera Trading Up 21.4%

Shares of NTRA traded up $56.72 during mid-day trading on Friday, reaching $322.10. The company’s stock had a trading volume of 3,385,814 shares, compared to its average volume of 1,072,972. Natera has a 52 week low of $149.38 and a 52 week high of $323.01. The stock has a market cap of $46.13 billion, a PE ratio of -236.84 and a beta of 1.51. The company’s fifty day moving average price is $254.03 and its two-hundred day moving average price is $223.79.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Revenue significantly exceeded expectations. Natera generated $752.8 million in second-quarter revenue, up 37.7% year over year and well above the $661.2 million analyst consensus. Gross margin also improved to 64.5% from 63.4% a year earlier. Natera Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The quarterly loss narrowed. Natera reported a loss of $0.47 per share, compared with a $0.74-per-share loss in the prior-year quarter, and better than the $0.49 loss expected by analysts. The result suggests continued operating improvement despite the company remaining unprofitable. Natera Reports Q2 Loss and Beats Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2026 revenue outlook to approximately $2.9 billion, above the roughly $2.8 billion consensus estimate. The higher guidance points to sustained momentum across Natera’s reproductive health, oncology, and transplant-testing businesses.
• Positive Sentiment: JPMorgan raised its price target on NTRA from $315 to $360 and maintained an “overweight” rating, signaling that the bank sees additional upside after the earnings beat. Benzinga
• Positive Sentiment: Natera submitted its Signatera bladder-cancer test to Japan’s PMDA for approval as a companion diagnostic. Clearance could expand the company’s international oncology market and create another source of long-term growth. Natera Submits Signatera to Japan’s PMDA
• Neutral Sentiment: Several executives sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. Because the sales were relatively small compared with their remaining holdings and were not discretionary open-market disposals, they provide limited negative information.
• Negative Sentiment: Natera remains unprofitable, and its very high valuation leaves the shares vulnerable to profit-taking if growth slows or future results fail to exceed elevated expectations. Commentary identifying NTRA as entering a potential profit-taking zone highlights this near-term risk. IBD 50 Stock Natera Profit-Taking Zone

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Robert W. Baird set a $348.00 price target on shares of Natera in a report on Friday. BTIG Research lifted their price objective on shares of Natera from $290.00 to $320.00 and gave the stock a “buy” rating in a report on Friday. Evercore reiterated an “outperform” rating and issued a $300.00 target price on shares of Natera in a research report on Monday, July 6th. The Goldman Sachs Group started coverage on Natera in a research note on Friday, June 5th. They issued a “neutral” rating and a $245.00 target price on the stock. Finally, William Blair began coverage on Natera in a research report on Tuesday, April 14th. They set an “outperform” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $299.65.

Insider Activity at Natera

In other Natera news, Director Gail Boxer Marcus sold 11,000 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the sale, the director directly owned 6,183 shares in the company, valued at $1,343,009.43. This represents a 64.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Steven Leonard Chapman sold 41,124 shares of the firm’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $221.03, for a total value of $9,089,637.72. Following the transaction, the chief executive officer directly owned 108,743 shares in the company, valued at $24,035,465.29. This trade represents a 27.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 181,045 shares of company stock worth $41,330,968 in the last 90 days. Corporate insiders own 5.05% of the company’s stock.

Institutional Investors Weigh In On Natera

Institutional investors have recently bought and sold shares of the stock. Sivia Capital Partners LLC bought a new position in Natera in the second quarter worth $298,000. CreativeOne Wealth LLC purchased a new stake in shares of Natera during the fourth quarter valued at $200,000. Smartleaf Asset Management LLC lifted its stake in Natera by 17.7% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the medical research company’s stock valued at $191,000 after acquiring an additional 125 shares during the period. Zions Bancorporation National Association UT bought a new position in Natera during the fourth quarter valued at approximately $85,000. Finally, Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its stake in shares of Natera by 27.1% in the 3rd quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 750 shares of the medical research company’s stock worth $121,000 after buying an additional 160 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.